E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Incidence of death, MI, ischemic stroke/Transient ischemic attack (TIA) or life threatening/major bleeding at 3-month follow-up. |
Incidencia de muerte, infarto de miocardio, accidente cerebrovascular isquémico, ataque isquemico transitorio o riesgo para la salud y sangrado. |
|
E.1.1.1 | Medical condition in easily understood language |
Risk of death, heart attack, cerebrovascular accident or bleeding. Time Frame: 3-month follow-up after transcatheter aortic valve implantation. |
Incidencia de muerte, infarto de miocardio, accidente cerebrovascular isquémico, ataque isquemico transitorio o riesgo para la salud y sangrado. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10013118 |
E.1.2 | Term | Diseases of aortic valve |
E.1.2 | System Organ Class | 100000004849 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare aspirin/acetylsalicylic acid+ clopidogrel with aspirin/acetylsalicylic acid alone as antithrombotic treatment following TAVI for the prevention of major ischemic events (MI, ischemic stroke) or death without increasing the risk of major bleeding events. |
Comparar la terapia antiagregante de aspirina + clopidogrel frente aspirina solo tras la IPPVA para la prevención de eventos isquémicos mayores (infarto e ictus isquémico) o muerte y el riesgo de eventos hemorrágicos mayores. |
|
E.2.2 | Secondary objectives of the trial |
Incidence of death, MI, ischemic stroke/Transient ischemic attack (TIA) or life threatening/major bleeding at 3-month follow-up. Incidence of death, MI, ischemic stroke/TIA or life threatening/major bleeding at 30 days Incidence of death, MI, ischemic stroke/TIA or life threatening/major bleeding at at 12-month follow-up Incidence of MI or ischemic stroke at 30 days and at 12-month follow-up Incidence of major bleeding at 30 days and at 12-month follow-up Cardiovascular death at 30 days and at 12-month follow-up Cost-effectiveness of clopidogrel on top of aspirin/acetylsalicylic acid following TAVI Rate of minor bleeding at 30 days and at 12-month follow-up |
Incidencia de mortalidad, infarto de miocardio, ictus isquémico/accidente isquémico transitorio (AIT) o hemorragia mayor/amenazante para la vida durante los primeros 3 meses tras la intervención. Incidencia de muerte, infarto de miocardio, ictus isquémico/AIT, o hemorragia mayor/amenazante para la vida en los primeros 30 días. Incidencia de infarto de miocardio o ictus isquémico a 30 días y 1 año de seguimiento. Incidencia de hemorragia mayor a 30 días y 1 año de seguimiento. Muerte cardiovascular a 30 días y 1 año de seguimiento. Coste efectividad del clopidogrel asociado a la aspirina tras la IPPVA. Tasa de hemorragia menor a 30 días y 1 año de seguimiento. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients undergoing a TAVI procedure with the Edwards valve. |
Pacientes sometidos a IPPVA con válvula Edwards (tanto por vía transfemoral, transapical u otros accesos). |
|
E.4 | Principal exclusion criteria |
-Need for chronic anticoagulation treatment -Major bleeding within the 3 months prior to the TAVI procedure -Prior intracranial bleeding -Drug-eluting stent implantation within the year prior to the TAVI procedure -Allergy to clopidogrel and/or aspirin/acetylsalicylic acid |
Necesidad de anticoagulación crónica. Hemorragia mayor en los 3 meses previos a la IPPVA Hemorragia intracraneal previa. Stent farmacoactivo en el último año previo al procedimiento. Alergia a la aspirina y/o clopidogrel |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Incidence of death, MI, ischemic stroke/Transient ischemic attack (TIA) or life threatening/major bleeding |
Incidencia de mortalidad, infarto de miocardio, ictus isquémico/accidente isquémico transitorio (AIT) o hemorragia mayor/amenazante para la vida |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
3-month follow-up |
a los 3 meses |
|
E.5.2 | Secondary end point(s) |
-Incidence of death, MI, ischemic stroke/TIA or life threatening/major bleeding -Incidence of MI or ischemic stroke -Incidence of major bleeding -Cardiovascular death -Cost-effectiveness of clopidogrel on top of aspirin following TAVI -Rate of minor bleeding |
Incidencia de muerte, infarto de miocardio, ictus isquémico/AIT, o hemorragia mayor/. Incidencia de hemorragia mayor Muerte cardiovascular Coste efectividad del clopidogrel asociado a la aspirina tras la IPPVA. Tasa de hemorragia menor |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
At 30 days and at 12-month follow-up |
Al mes y al año |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 6 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 6 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |